Gilead Sciences (GILD) EPS (Weighted Average and Diluted) Growth (5y) (2014 - 2026)

Gilead Sciences (GILD) EPS (Weighted Average and Diluted) Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 3.28%
Dec 31, 2025 7.18%
Sep 30, 2025 52.98%
Jun 30, 2025 20.93%
Mar 31, 2025 -3.14%
Dec 31, 2024 -7.70%
Sep 30, 2024 25.29%
Jun 30, 2024 -2.58%
Mar 31, 2024 -33.05%
Dec 31, 2023 39.38%
Sep 30, 2023 1.57%
Jun 30, 2023 -9.80%
Mar 31, 2023 -7.32%
Dec 31, 2022 19.52%
Sep 30, 2022 -7.17%
Jun 30, 2022 -17.14%
Mar 31, 2022 -60.39%
Dec 31, 2021 -33.69%
Sep 30, 2021 -3.81%
Jun 30, 2021 -14.05%